



PPD Awarded DAIDS Contract for Global HIV Clinical Research Management

Selected to provide comprehensive support to the NIAID Division of AIDS

WILMINGTON, N.C. (July 18, 2005) - PPD, Inc. (Nasdaq: PPDI) today announced it has been awarded a five-year contract (NIH-NIAID-DAIDS-05-06) to provide comprehensive research management and support to the National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS (DAIDS). NIAID is a component of the National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services.

PPD will work with DAIDS and its other contractors to facilitate clinical research management that integrates work being carried out by both clinical network and non-network systems, which includes existing trial networks as well as individual investigators in eight regions of the world. Research areas include treatment for AIDS in adult and pediatric patients, strategies to prevent disease transmission including mother to child transmission and development of vaccines.

PPD will provide direct labor support based in the U.S., Europe, South America, South Africa, Australia, China, Thailand and India. The projected total value of the contract is approximately **\$245 million**, of which an estimated \$43 million would be subcontractor costs.

"We are extremely pleased to have been chosen to support DAIDS in this important and challenging work," said Fred Eshelman, chief executive officer of PPD. "A program of such magnitude provides a unique opportunity to assist DAIDS with its global agenda to transform the face of HIV through its international infrastructure, widespread physician training, clinical research and employment of disease prevention strategies."

PPD has supported DAIDS on a number of other HIV contracts since 1990.

As a leading global provider of discovery and development services and products for pharmaceutical, biotechnology and medical device companies, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients maximize the return on their R&D investments. With proven discovery through post-market resources, the company also offers compound partnering opportunities. PPD has more than 7,100 professionals worldwide with offices in 28 countries. For more information on PPD, visit our Web site at <http://www.ppd.com>.

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the value of this contract, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: loss of large contracts; increased cancellation rates; the ability to attract and retain key personnel; competition within the outsourcing industry; continued success in sales growth; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Media

Nancy Zeleniak

+919 462 4088

nancy.zeleniak@rtp.ppd.com

Analysts/Investors

Steve Smith

+910 772 7585

stephen.smith@wilm.ppd.com